<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01925235</url>
  </required_header>
  <id_info>
    <org_study_id>Ren-PRO TAVI retro</org_study_id>
    <nct_id>NCT01925235</nct_id>
  </id_info>
  <brief_title>Analysis of Remote-ischemic Preconditioning Effects on Kidney Function</brief_title>
  <acronym>RenPRO-TAVI</acronym>
  <official_title>Remote Ischemic Preconditioning Effects on Kidney Function in Patients Receiving Transcatheter Aortic Valve Implantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cologne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cologne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with impaired renal function are at elevated risk for development of acute kidney
      injury (AKI). AKI is associated with increased risk for cardiovascular morbidity and
      mortality. Effective AKI prevention strategies are needed. Remote ischemic preconditioning
      (RIPC) is a novel and successful strategy to attenuate contrast medium induced AKI in
      patients undergoing elective coronary angiography.

      The retrospective RenPro-TAVI Trial was designed to test the hypothesis whether remote
      ischemic preconditioning might attenuate kidney injury in patients receiving transcatheter
      aortic valve implantation (TAVI).

      Patients with impaired renal function undergoing TAVI will be evaluated in respect whether
      they received remote ischemic preconditioning before the procedure or not. This study will
      give insight if RIPC might be beneficial in these patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>change in parameters determining renal function and injury</measure>
    <time_frame>48 hours after TAVI</time_frame>
    <description>serum creatinine, cystatin c, urinary neutrophil gelatinase-associated lipocalin (NGAL)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>acute kidney injury</measure>
    <time_frame>48 hours after TAVI</time_frame>
    <description>increase in serum creatinine ≥25% or ≥0.5 mg/dL above baseline at 48 hours after TAVI</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">18</enrollment>
  <condition>Renal Function</condition>
  <condition>Renal Injury</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>patients with impaired renal function and a high risk of developing acute kidney injury undergoing TAVI and receiving standard care including pre-hydration 12 hours prior and 12 hours post procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RIPC</arm_group_label>
    <description>patients with impaired renal function and a high risk of developing acute kidney injury undergoing TAVI and receiving standard care including pre-hydration 12 hours prior and 12 hours post procedure plus ischemic preconditioning (intermittent arm ischemia through 4 cycles of 5-minute inflation and 5-minute deflation of a blood pressure cuff)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>remote ischemic preconditioning</intervention_name>
    <arm_group_label>RIPC</arm_group_label>
    <other_name>intermittent arm ischemia through 4 cycles of 5-minute inflation and 5-minute deflation of a blood pressure cuff</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with impaired renal function and a high risk of developing contrast medium-induced
        acute kidney injury undergoing TAVI
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt;= 18 years

          -  impaired renal function (baseline eGFR of &lt;60 ml/min)

          -  high INTEGER risk score &gt; 11

          -  high EuroSCORE (European system for cardiac operative risk evaluation)

        Exclusion Criteria:

          -  severe renal impairment (eGFR &lt;15 ml/min and/or in chronic dialysis)

          -  recent (&lt;=30 days) contrast media exposure

          -  patients enrolled in concomitant studies

          -  fertile women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital of Cologne</name>
      <address>
        <city>Cologne</city>
        <state>NRW</state>
        <zip>50931</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Er F, Nia AM, Dopp H, Hellmich M, Dahlem KM, Caglayan E, Kubacki T, Benzing T, Erdmann E, Burst V, Gassanov N. Ischemic preconditioning for prevention of contrast medium-induced nephropathy: randomized pilot RenPro Trial (Renal Protection Trial). Circulation. 2012 Jul 17;126(3):296-303. doi: 10.1161/CIRCULATIONAHA.112.096370. Epub 2012 Jun 26.</citation>
    <PMID>22735306</PMID>
  </reference>
  <reference>
    <citation>Er F, Nia AM, Dopp H, Dahlem KM, Caglayan E, Erdmann E, Gassanov N, Hellmich M, Burst V, Kubacki T, Benzing T. Response to letter regarding article, &quot;Ischemic preconditioning for prevention of contrast medium-induced nephropathy: randomized Pilot RenPro-Trial (Renal Protection Trial)&quot;. Circulation. 2013 Apr 2;127(13):e536.</citation>
    <PMID>23662313</PMID>
  </reference>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2013</study_first_submitted>
  <study_first_submitted_qc>August 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2013</study_first_posted>
  <last_update_submitted>August 16, 2013</last_update_submitted>
  <last_update_submitted_qc>August 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cologne</investigator_affiliation>
    <investigator_full_name>Dr. Fikret Er</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>remote ischemic preconditioning</keyword>
  <keyword>acute kidney injury</keyword>
  <keyword>TAVI</keyword>
  <keyword>RenPRO trial</keyword>
  <keyword>parameters</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

